Researchers Submit Patent Application, "Methods Of Administering Genetically Modified B Cells For In Vivo Delivery Of Therapeutic Agents", for Approval (USPTO 20230414659).
In: Gene Therapy Weekly, 2024-01-15, S. 2782-2782
serialPeriodical
Zugriff:
A patent application has been submitted for methods of administering genetically modified B cells to deliver therapeutic agents to the central nervous system (CNS). The application describes different ways of administering the cells, such as through infusion into the cerebrospinal fluid or through various types of injections. The genetically modified B cells can be created using different techniques, such as gene editing or viral vector-mediated delivery. The application also suggests that these cells could be used to treat diseases associated with lysosomal storage dysfunction, like mucopolysaccharidosis type I. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Methods Of Administering Genetically Modified B Cells For In Vivo Delivery Of Therapeutic Agents", for Approval (USPTO 20230414659).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-01-15, S. 2782-2782 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|